Latest Soleus Capital Management, L.P. Stock Portfolio

Soleus Capital Management, L.P. Performance:

2025 Q4: 29.34%YTD: 25.13%2024: 2.36%

Performance for 2025 Q4 is 29.34%, and YTD is 25.13%, and 2024 is 2.36%.

About Soleus Capital Management, L.P. and 13F Hedge Fund Stock Holdings

On 2026-02-12, the fund reported it's updated stock portfolio. In the 13F Holdings report, Soleus Capital Management, L.P. reported an equity portfolio of $2.7 Billions as of 31 Dec, 2025.

The top stock holdings of Soleus Capital Management, L.P. are KRYS, CELC, NVCR. The fund has invested 8.6% of it's portfolio in KRYSTAL BIOTECH INC and 6.7% of portfolio in CELCUITY INC.

The fund managers got completely rid off ELEVANCE HEALTH INC FORMERLY (ANTX), GRIFOLS S A (GIKLY) and INTEGRA LIFESCIENCES HLDGS C (IART) stocks. They significantly reduced their stock positions in MADRIGAL PHARMACEUTICALS INC (MDGL), VERACYTE INC (VCYT) and LB PHARMACEUTICALS INC. Soleus Capital Management, L.P. opened new stock positions in DEXCOM INC (DXCM), INSULET CORP (PODD) and ALKERMES PLC (ALKS). The fund showed a lot of confidence in some stocks as they added substantially to TREVI THERAPEUTICS INC (TRVI), SEPTERNA INC and INSMED INC (INSM).

Soleus Capital Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Soleus Capital Management, L.P. made a return of 29.34% in the last quarter. In trailing 12 months, it's portfolio return was 25.13%.

Performance
S&P 500

New Buys

Ticker	$ Bought
dexcom inc	86,088,100
insulet corp	42,636,000
alkermes plc	36,999,700
livanova plc	34,918,300
immunovant inc	28,216,200
vaxcyte inc	28,097,300
teleflex incorporated	23,187,600
edgewise therapeutics inc	22,581,600

New stocks bought by Soleus Capital Management, L.P.

Additions

Ticker	% Inc.
trevi therapeutics inc	3,500
septerna inc	1,999
insmed inc	1,801
globus med inc	403
alnylam pharmaceuticals inc	359
orthopediatrics corp	310
kiniksa pharmaceuticals intl	291
mirum pharmaceuticals inc	285

Additions to existing portfolio by Soleus Capital Management, L.P.

Reductions

Ticker	% Reduced
madrigal pharmaceuticals inc	-99.27
veracyte inc	-97.63
lb pharmaceuticals inc	-97.5
terns pharmaceuticals inc	-97.38
tango therapeutics inc	-96.67
staar surgical co	-95.00
indivior plc	-93.18
cidara therapeutics inc	-92.14

Soleus Capital Management, L.P. reduced stake in above stock

Sold off

Ticker	$ Sold
essa pharma inc	-833,147
grifols s a	-24,900,000
immunic inc	-1,392,930
integra lifesciences hldgs c	-20,646,900
iovance biotherapeutics inc	-2,119,450
verastem inc	-8,264,080
adma biologics inc	-10,819,100
myomo inc	-628,213

Soleus Capital Management, L.P. got rid off the above stocks

Sector Distribution

Soleus Capital Management, L.P. has about 86.4% of it's holdings in Healthcare sector.

Sector	%
Healthcare	86.4
Others	12.8

Market Cap. Distribution

Soleus Capital Management, L.P. has about 17% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	43.1
SMALL-CAP	24.8
LARGE-CAP	17
UNALLOCATED	12.8
MICRO-CAP	2.2

Stocks belong to which Index?

About 60.1% of the stocks held by Soleus Capital Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	53.7
Others	39.9
S&P 500	6.4

Top 5 Winners (%)		%
PRAX	praxis precision medicines i	324.4 %
TERN	terns pharmaceuticals inc	224.7 %
	calcimedica inc	114.3 %
OLMA	olema pharmaceuticals inc	86.4 %
NRIX	nurix therapeutics inc	79.2 %

Top 5 Winners ($)		$
PRAX	praxis precision medicines i	147.7 M
TERN	terns pharmaceuticals inc	137.1 M
CELC	celcuity inc	75.2 M
KRYS	krystal biotech inc	68.6 M
	beta bionics inc	33.9 M

Top 5 Losers (%)		%
NSPR	inspiremd inc	-23.3 %
TGTX	tg therapeutics inc	-15.9 %
ACLX	arcellx inc	-13.4 %
JSPR	jasper therapeutics inc	-13.1 %
ANIP	ani pharmaceuticals inc	-12.0 %

Top 5 Losers ($)		$
TGTX	tg therapeutics inc	-22.1 M
ANIP	ani pharmaceuticals inc	-5.2 M
ALNY	alnylam pharmaceuticals inc	-2.5 M
CCCC	c4 therapeutics inc	-1.7 M
ACLX	arcellx inc	-1.1 M

Soleus Capital Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Soleus Capital Management, L.P.

Soleus Capital Management, L.P. has 94 stocks in it's portfolio. About 41.2% of the portfolio is in top 10 stocks. TGTX proved to be the most loss making stock for the portfolio. PRAX was the most profitable stock for Soleus Capital Management, L.P. last quarter.

Last Reported on: 12 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ACLX	arcellx inc	0.07	30,000	1,956,000	reduced	-70.00

ADGI	invivyd inc	0.70	7,708,730	19,040,600	new

ADMA	adma biologics inc	0.00	0.00	0.00	sold off	-100

ADVM	adverum biotechnologies inc	0.00	0.00	0.00	sold off	-100

AKRO	akero therapeutics inc	0.00	0.00	0.00	sold off	-100

ALKS	alkermes plc	1.36	1,322,360	36,999,700	new

ALNY	alnylam pharmaceuticals inc	1.03	70,000	27,835,500	added	359

ANAB	anaptysbio inc	0.24	135,000	6,544,800	reduced	-78.44

ANIP	ani pharmaceuticals inc	1.42	486,243	38,384,000	added	42.91

ANTX	elevance health inc formerly	0.00	0.00	0.00	sold off	-100

ARGX	argenx se	0.98	31,726	26,680,000	reduced	-54.3

AVTE	jade biosciences inc	0.45	796,744	12,293,800	unchanged	0.00

AVTX	avalo therapeutics inc	0.30	441,978	8,026,320	new

AXGN	axogen inc	1.46	1,206,860	39,500,400	reduced	-30.1

BLTE	belite bio inc	0.24	40,354	6,455,030	reduced	-80.78

BMRN	biomarin pharmaceutical inc	2.89	1,320,000	78,447,600	added	48.26

CAPR	capricor therapeutics inc	0.69	646,390	18,654,800	new

CCCC	c4 therapeutics inc	0.27	3,803,940	7,265,530	reduced	-46.07

CDTX	cidara therapeutics inc	0.32	38,811	8,572,960	reduced	-92.14

CELC	celcuity inc	6.65	1,808,260	180,356,000	added	53.39